Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls

Clinical Science

Volumn 121, Issue 11, 2011, Pages 501-507

  Ward, Natalie C ^a   Croft, Kevin D ^a   Blacker, David ^a,b   Hankey, Graeme J ^a,b   Barden, Anne ^a   Mori, Trevor A ^a   Puddey, Ian B ^a,c   Beer, Christopher D ^a,c,d,e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

20 hydroxyeicosatetraenoic acid (20 HETE); Acute ischaemic stroke; Arachidonic acid; Cytochrome P450 (CYP450); Dihydroxyeicosatetraenoic acid (DiHETE); Epoxyeicosatrienoic acid (EET); Oxidative stress

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID DERIVATIVE; CYTOCHROME P450; DIHYDROXYICOSATETRAENOIC ACID; EPOXYICOSATRIENOIC ACID; ISOPROSTANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; STROKE;

8,11,14-EICOSATRIENOIC ACID; ARACHIDONIC ACID; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; F2-ISOPROSTANES; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MALE; MIDDLE AGED; OXIDATIVE STRESS; STROKE;

EID: 80052366570     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20110215     Document Type: Article

References (25)

1. van der Worp, H. B. and van Gijn, J. (2007) Clinical practice. Acute ischemic stroke. N. Engl. J. Med. 357, 572-579
2. Pilitsis, J. G., Coplin, W. M., O'Regan, M. H., Wellwood, J. M., Diaz, F. G., Fairfax, M. R., Michael, D. B. and Philis, J.W. (2003) Measurement of free fatty acids in cerebrospinal fluid from patients with hemorrhagic and ischemic stroke. Brain Res. 985, 198-201
3. Roman, R. J. (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82, 131-185
4. McGiff, J. C. and Quilley, J. (2001) 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr. Opin. Nephrol. Hypertens. 10, 231-237
5. Stec, D. E., Roman, R. J., Flasch, A. and Rieder,M. J. (2007) Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol. Genomics 30, 74-81
6. Fleming, I. (2001) Cytochrome p450 and vascular homeostasis. Circ. Res. 89, 753-762
7. Morrow, J. D. and Roberts, L. J. (1997) The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36, 1-21
8. Dunn, K. M., Renic, M., Flasch, A. K., Harder, D. R., Falck, J. and Roman, R. J. (2008) Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am. J. Physiol. 295, H2455-H2465
9. Renic, M., Klaus, J. A., Omura, T., Kawashima, N., Onishi, M., Miyata, N., Koehler, R. C., Harder, D. R. and Roman, R. J. (2009) Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 29, 629-639
10. Marumo, T., Eto, K., Wake, H., Omura, T. and Nabekura, J. (2010) The inhibitor of 20-HETE synthesis, TS-011, improves cerebral microcirculatory autoregulation impaired by middle cerebral artery occlusion in mice. Br. J. Pharmacol. 161, 1391-1402
11. Fava, C., Montagnana, M., Almgren, P., Rosberg, L., Lippi, G., Hedblad, B., Engstrom, G., Berglund, G., Minuz, P. and Melander, O. (2008) The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension 52, 373-380
12. Deng, S., Zhu, G., Liu, F., Zhang, H., Qin, X., Li, L. and Zhiyi, H. (2010) CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 664-668
13. Fu, Z., Nakayama, T., Sato, N., Izumi, Y., Kasamaki, Y., Shindo, A., Ohta, M., Soma, M., Aoi, N., Matsumoto, K. et al. (2008) A haplotype of the CYP4F2 gene is associated with cerebral infarction in Japanese men. Am. J. Hypertens. 21, 1216-1223
14. Ward, N. C., Tsai, I. J., Barden, A., van Bockxmeer, F. M., Puddey, I. B., Hodgson, J. M. and Croft, K. D. (2008) A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension 51, 1393-1398
15. Koerner, I. P., Jacks, R., DeBarber, A. E., Koop, D., Mao, P., Grant, D. F. and Alkayed, N. J. (2007) Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J. Neurosci. 27, 4642-4649
16. Iliff, J. J.,Wang, R., Zeldin, D. C. and Alkayed, N. J. (2009) Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels. Am. J. Physiol. Heart Circ. Physiol. 296, H1352-H1363
17. Adams, Jr, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D. L. and Marsh, E. E. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 24, 35-41
18. Tsai, I. J., Croft, K. D., Mori, T. A., Falck, J. R., Beilin, L. J., Puddey, I. B. and Barden, A. E. (2009) 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction. Free Radical Biol. Med. 46, 263-270
19. Ward, N. C., Rivera, J., Hodgson, J., Puddey, I. B., Beilin, L. J., Falck, J. R. and Croft, K. D. (2004) Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 110, 438-443
20. Lee,C. Y., Seet, R. C.,Huang, S.H., Long, L. H. and Halliwell, B. (2009) Different patterns of oxidized lipid products in plasma and urine of dengue fever, stroke, and Parkinson's disease patients: cautions in the use of biomarkers of oxidative stress. Antioxid. Redox Signaling 11, 407-420
21. Quilley, J. and McGiff, J. C. (2000) Is EDHF an epoxyeicosatrienoic acid? Trends Pharmacol. Sci. 21, 121-124
22. Zhang, W., Koerner, I. P., Noppens, R., Grafe, M., Tsai, H. J., Morisseau, C., Luria, A., Hammock, B. D., Falck, J. R. and Alkayed, N. J. (2007) Soluble epoxide hydrolase: a novel therapeutic target in stroke. J. Cereb. Blood Flow Metab. 27, 1931-1940
23. Zhang, W., Otsuka, T., Sugo, N., Ardeshiri, A., Alhadid, Y. K., Iliff, J. J., DeBarber, A. E., Koop, D. R. and Alkayed, N. J. (2008) Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 39, 2073-2078
24. Sarkis, A. and Roman, R. J. (2004) Role of cytochrome P450 metabolites of arachidonic acid in hypertension. Curr. Drug Metab. 5, 245-256
25. Kelly, P. J., Morrow, J. D., Ning, M., Koroshetz, W., Lo, E. H., Terry, E., Milne, G. L., Hubbard, J., Lee, H., Stevenson, E. et al. (2008) Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the biomarker evaluation for antioxidant therapies in stroke (BEAT-Stroke) study. Stroke 39, 100-104